FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1846002509> ?p ?o ?g. }

• W1846002509 endingPage "65" @default.
• W1846002509 startingPage "2357" @default.
• W1846002509 abstract "T helper (Th) 1/Th2 balance, controlled by Th1 or Th2 cells producing cytokines, plays important roles in antitumor immunity. Interleukin-18 (IL-18) can act together with IL-12 in promoting the generation of IFN-gamma producing Th1 cells. The goal of this study was to determine whether cytotoxic T lymphocyte (CTL) secreted in a murine IL-18-induced Th1-dominant state inhibited the development of primary tumors and synchronous liver metastases in orthotopic colon cancer model.Murine IL-18 gene was transduced into activated T lymphocytes by an adenovirus vector encoding IL-18 (AdIL-18) liposome complex method. Efficacy of adoptive immunogene therapy using AdIL-18 with or without IL-12 was tested in advanced orthotopic xenograft of murine colon cancer. To elucidate the mechanism responsible for the adoptive immunogene therapy, serum IL-4, IL-6, IFN-gamma, and tumor necrosis factor alpha production in Th1/Th2 cytokine balance and quantification of tumor vascularity were investigated.By a modified method of adenoviral gene transduction, T lymphocytes achieved efficient IL-18 production without cell toxicity. Against orthotopic colon cancer, when combined with low dose of recombinant (r) IL-12 (AdIL-18-CTL/rIL-12), the therapeutic efficacy showed much smaller tumors with no liver metastases and no disseminated tumors. There was a significant difference in the volume of primary tumors and the number of liver metastases compared with the group treated with AdIL-18-CTL alone or other group (P < 0.01). In addition, the median survival time of the group treated with AdIL-18-CTL was 53.7 +/- 5.8 days and that of AdIL-18-CTL/rIL-12 was 78.4 +/- 6.1 days, which was also a significant difference (P < 0.01). These antitumor mechanisms were involved with Th1-dominant response in serum Th1/Th2 cytokine balance and suppression of neovascularization at primary tumor site.These data suggest that a strategy of Th1/Th2 balance-based adoptive immunogene therapy might be useful for advanced cancer patients." @default.
• W1846002509 created "2016-06-24" @default.
• W1846002509 creator A5013419903 @default.
• W1846002509 creator A5018595476 @default.
• W1846002509 creator A5018774452 @default.
• W1846002509 creator A5035411012 @default.
• W1846002509 creator A5073275097 @default.
• W1846002509 creator A5087155470 @default.
• W1846002509 date "2003-06-01" @default.
• W1846002509 modified "2023-09-23" @default.
• W1846002509 title "Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer." @default.
• W1846002509 cites W1485835599 @default.
• W1846002509 cites W1551774211 @default.
• W1846002509 cites W1559289707 @default.
• W1846002509 cites W1571169370 @default.
• W1846002509 cites W1576968639 @default.
• W1846002509 cites W1628876078 @default.
• W1846002509 cites W1684070912 @default.
• W1846002509 cites W1772349866 @default.
• W1846002509 cites W1883998319 @default.
• W1846002509 cites W1929577730 @default.
• W1846002509 cites W1965712272 @default.
• W1846002509 cites W1971037354 @default.
• W1846002509 cites W1977889585 @default.
• W1846002509 cites W1996150072 @default.
• W1846002509 cites W1997403488 @default.
• W1846002509 cites W1998105611 @default.
• W1846002509 cites W2021667186 @default.
• W1846002509 cites W2026161448 @default.
• W1846002509 cites W2028701135 @default.
• W1846002509 cites W2037230449 @default.
• W1846002509 cites W2042352158 @default.
• W1846002509 cites W2042921906 @default.
• W1846002509 cites W2048162805 @default.
• W1846002509 cites W2053349737 @default.
• W1846002509 cites W2077989877 @default.
• W1846002509 cites W2091566739 @default.
• W1846002509 cites W2111647992 @default.
• W1846002509 cites W2112789179 @default.
• W1846002509 cites W2120427107 @default.
• W1846002509 cites W2129623992 @default.
• W1846002509 cites W2134139967 @default.
• W1846002509 cites W2141377922 @default.
• W1846002509 cites W2141967996 @default.
• W1846002509 cites W2142294608 @default.
• W1846002509 cites W2149579127 @default.
• W1846002509 cites W2155120317 @default.
• W1846002509 cites W2166037275 @default.
• W1846002509 cites W2171831396 @default.
• W1846002509 cites W2172569601 @default.
• W1846002509 cites W2181724034 @default.
• W1846002509 cites W2319534054 @default.
• W1846002509 cites W2328691057 @default.
• W1846002509 cites W2332084345 @default.
• W1846002509 cites W2334225662 @default.
• W1846002509 cites W85728599 @default.
• W1846002509 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12796406" @default.
• W1846002509 hasPublicationYear "2003" @default.
• W1846002509 type Work @default.
• W1846002509 sameAs 1846002509 @default.
• W1846002509 citedByCount "7" @default.
• W1846002509 countsByYear W18460025092015 @default.
• W1846002509 countsByYear W18460025092016 @default.
• W1846002509 crossrefType "journal-article" @default.
• W1846002509 hasAuthorship W1846002509A5013419903 @default.
• W1846002509 hasAuthorship W1846002509A5018595476 @default.
• W1846002509 hasAuthorship W1846002509A5018774452 @default.
• W1846002509 hasAuthorship W1846002509A5035411012 @default.
• W1846002509 hasAuthorship W1846002509A5073275097 @default.
• W1846002509 hasAuthorship W1846002509A5087155470 @default.
• W1846002509 hasConcept C104317684 @default.
• W1846002509 hasConcept C111599444 @default.
• W1846002509 hasConcept C121608353 @default.
• W1846002509 hasConcept C126322002 @default.
• W1846002509 hasConcept C147969180 @default.
• W1846002509 hasConcept C154317977 @default.
• W1846002509 hasConcept C167672396 @default.
• W1846002509 hasConcept C202751555 @default.
• W1846002509 hasConcept C203014093 @default.
• W1846002509 hasConcept C2776090121 @default.
• W1846002509 hasConcept C2777701055 @default.
• W1846002509 hasConcept C2778326572 @default.
• W1846002509 hasConcept C2778690821 @default.
• W1846002509 hasConcept C502942594 @default.
• W1846002509 hasConcept C526805850 @default.
• W1846002509 hasConcept C55493867 @default.
• W1846002509 hasConcept C71924100 @default.
• W1846002509 hasConcept C86803240 @default.
• W1846002509 hasConcept C8891405 @default.
• W1846002509 hasConcept C90375314 @default.
• W1846002509 hasConceptScore W1846002509C104317684 @default.
• W1846002509 hasConceptScore W1846002509C111599444 @default.
• W1846002509 hasConceptScore W1846002509C121608353 @default.
• W1846002509 hasConceptScore W1846002509C126322002 @default.
• W1846002509 hasConceptScore W1846002509C147969180 @default.
• W1846002509 hasConceptScore W1846002509C154317977 @default.
• W1846002509 hasConceptScore W1846002509C167672396 @default.
• W1846002509 hasConceptScore W1846002509C202751555 @default.

• next